ANCA Status or Clinical Phenotype - What Counts More?

Area of Science:

• Immunology
• Rheumatology
• Nephrology

Background:

• Antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis classification is debated.
• Current classification considers either serotype (PR3- or MPO-ANCA) or clinical phenotype (GPA or MPA).

Purpose of the Study:

• To review recent literature and provide clarity on ANCA-associated vasculitis classification.
• To evaluate the predictive value of serotype versus phenotype in ANCA-associated vasculitis.

Main Methods:

• Review of recent clinical trials and observational studies.
• Integration of the latest scientific literature on ANCA-associated vasculitis.

Main Results:

• Serology-based risk assessment is more predictive of relapses than phenotype-based distinction.
• Serotype-based classification aligns better with genetic associations, clinical presentation, biomarker biology, and treatment response.
• Serotype-based approach also predicts comorbidities like cardiovascular death.

Conclusions:

• A serology-based approach may replace the phenotype-based approach for classifying ANCA-associated vasculitis.
• Future research and clinical trials are expected to focus on serotype-based distinctions.
• This shift could lead to more personalized medicine for ANCA-associated vasculitis.